Skip to main content

Advertisement

SpringerLink
Log in

Evolving Role of Gene Expression Signatures as Biomarkers in Early-Stage Colon Cancer

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Colorectal cancer (CRC) is a major health problem in the USA and worldwide. At the time of initial presentation, approximately 26 % of CRC patients will have stage II disease while another 30 % will present with stage III disease. Although surgical resection plays a critical role in the management of patients who have early-stage disease, it is usually not curative by itself. As a result, adjuvant chemotherapy is generally administered to eradicate clinically occult micrometastatic disease. It is now being increasingly realized that not all patients with stage II and III disease derive significant benefit from adjuvant chemotherapy. Moreover, due to a growing concern for long-term chemotherapy-associated adverse effects, its utility in unselected stage II/III patients is now being questioned.

Methodology and Results

Significant efforts have been made in recent years to identify potential biomarkers that would help to define the subset of stage II and III colon cancer patients expected to derive significant benefit from adjuvant chemotherapy, especially in those with borderline indications. Oncotype DX Colon Cancer Assay and ColoPrint are gene expression profiling-based recurrence score (RS) assays that have been developed with this intent. The greatest utility of RS assay has been conventionally believed to be for identifying recurrence risk in stage II patients. Recent data now suggests that stage III patients similar to stage II patients, vary in their tumor recurrence risk and that there might be a role for a more selective approach in treating these patients, based on the results of RS assays.

Conclusion

In such an evolving landscape, this article aims to review the current role of gene expression signatures such as Oncotype DX and ColoPrint in the management of early-stage colon cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.

    Article  CAS  PubMed  Google Scholar 

  3. Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, et al. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res. 2001;61:818–22.

    CAS  PubMed  Google Scholar 

  4. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.

    Article  CAS  PubMed  Google Scholar 

  5. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–22.

    CAS  PubMed  Google Scholar 

  6. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer. 1998;79:390–5.

    Article  CAS  PubMed  Google Scholar 

  7. Fishel R. Mismatch repair, molecular switches, and signal transduction. Genes Dev. 1998;12:2096–101.

    Article  CAS  PubMed  Google Scholar 

  8. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, et al. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 2002;15:741–9.

    Article  PubMed  Google Scholar 

  9. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006;30:1175–83.

    Article  PubMed  Google Scholar 

  10. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.

    Article  PubMed  Google Scholar 

  11. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61:561–9.

    CAS  PubMed  Google Scholar 

  12. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.

    Article  CAS  PubMed  Google Scholar 

  13. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    Article  CAS  PubMed  Google Scholar 

  14. Benson 3rd AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.

    Article  PubMed  Google Scholar 

  15. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–7.

    Article  CAS  PubMed  Google Scholar 

  16. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009 11: 35–41.

  17. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.

    Article  CAS  PubMed  Google Scholar 

  18. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003;22:9192–6.

    Article  CAS  PubMed  Google Scholar 

  20. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.

    Article  CAS  PubMed  Google Scholar 

  22. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.

    Article  CAS  PubMed  Google Scholar 

  23. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.

    Article  CAS  PubMed  Google Scholar 

  24. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, etal. (2010) AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition. Springer, New York. p. 143.

  26. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.

    Article  CAS  PubMed  Google Scholar 

  27. Salazar R, Roepman P, Capella G, Moreno V, Simon I, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29:17–24.

    Article  PubMed  Google Scholar 

  28. Salazar R, Tabernero J, Moreno V, Nitsche U Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients. J Clin Oncol 2012; 30:abstract 3510.

  29. O’Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937–44.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:4611–9.

    Article  PubMed  Google Scholar 

  31. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31:1775–81.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Yothers G, O’Connell MJ, Lee M, Lopatin M, Clark-Langone KM, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31:4512–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Ethical Standards

The manuscript does not contain clinical studies or patient data.

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Room 463, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA

    Gaurav Goel

  2. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Gaurav Goel

Authors
  1. Gaurav Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gaurav Goel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goel, G. Evolving Role of Gene Expression Signatures as Biomarkers in Early-Stage Colon Cancer. J Gastrointest Canc 45, 399–404 (2014). https://doi.org/10.1007/s12029-014-9634-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-014-9634-7

Keywords

Search

Navigation